(S)-1-(3-chlorophenyl)-4-(2-methyl-3-phenoxypropoxy)pyridin-2(1H)-one

ID: ALA4520808

PubChem CID: 155542406

Max Phase: Preclinical

Molecular Formula: C21H20ClNO3

Molecular Weight: 369.85

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H](COc1ccccc1)COc1ccn(-c2cccc(Cl)c2)c(=O)c1

Standard InChI:  InChI=1S/C21H20ClNO3/c1-16(14-25-19-8-3-2-4-9-19)15-26-20-10-11-23(21(24)13-20)18-7-5-6-17(22)12-18/h2-13,16H,14-15H2,1H3/t16-/m1/s1

Standard InChI Key:  OOUZESCBMLGWKJ-MRXNPFEDSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
    3.7194   -9.8415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7182  -10.6689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4330  -11.0818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1495  -10.6684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1466   -9.8379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4312   -9.4287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8645  -11.0797    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.5784  -10.6661    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2934  -11.0775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0073  -10.6639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7224  -11.0753    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.4362  -10.6617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1462  -11.0762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8579  -10.6660    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8609   -9.8407    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.1459   -9.4271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4280   -9.8389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1474   -8.6021    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.5741   -9.4319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2880   -9.8477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.0029   -9.4374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.0051   -8.6116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2865   -8.1977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5746   -8.6103    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2948  -11.9025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.7163   -9.8518    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 12 17  2  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 16 18  2  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 19  1  0
 15 19  1  0
  9 25  1  6
 21 26  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4520808

    ---

Associated Targets(non-human)

Grm3 Metabotropic glutamate receptor 3 (981 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 369.85Molecular Weight (Monoisotopic): 369.1132AlogP: 4.58#Rotatable Bonds: 7
Polar Surface Area: 40.46Molecular Species: NEUTRALHBA: 4HBD:
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: 4.40CX LogD: 4.40
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.61Np Likeness Score: -0.99

References

1. Yamada Y, Yohn SE, Gilliland K, Loch MT, Schulte ML, Rodriguez AL, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW..  (2019)  Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu3 NAMs: Challenging SAR, enantiospecific activity and in vivo efficacy.,  29  (18): [PMID:31358468] [10.1016/j.bmcl.2019.07.030]

Source